Publication: Long term follow-up of international randomised phase 3 study of rituximab versus a watch and wait approach for patients with asymptomatic, low tumour burden follicular lymphoma shows rituximab is highly effective at delaying time to new treatment without detrimental impact following next line of therapy
Program
KU-Authors
KU Authors
Co-Authors
Northend, Michael
Wilson, William
Clifton-Hadley, Laura
Rana, Zaynab
Martin, Tanya-Louise
Young, Moya
Miall, Fiona
Cunningham, David
Walewski, Jan
Johnston, Amanda
Editor & Affiliation
Compiler & Affiliation
Translator
Other Contributor
Date
Language
Type
Embargo Status
N/A
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
BAKILACAK
Source
Publisher
American Society of Hematology (ASH)
Subject
Hematology
Citation
Has Part
Source
Blood
Book Series Title
Edition
DOI
10.1182/blood-2022-156790
item.page.datauri
Link
Rights
N/A